NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC

This open-label, single-arm study is designed to evaluate the safety and preliminary efficacy of NK010 cell injection combined with a PD-1 antibody and platinum-based chemotherapy as neoadjuvant therapy in patients with resectable non-small cell lung cancer (NSCLC). The study aims to assess the safety profile, feasibility of administration, and potential antitumor activity of this combination regimen.

NCT Number	NCT07318636
Lead Sponsor	The First Affiliated Hospital of Guangzhou Medical University Collaborators: Shanghai NK Cell Technology Co., LTD
Conditions	Resectable Non-small Cell Lung Cancer
Enrollment	10 participants
Start Date	2026-01-20
Primary Completion	2026-12-30 (estimated)
Study Completion	2027-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-06